Journal
CHINESE JOURNAL OF CANCER
Volume 36, Issue -, Pages -Publisher
SUN YAT SEN UNIV MED SCI WHO
DOI: 10.1186/s40880-017-0184-9
Keywords
Metformin; Signaling pathway; Cancer stem cell; Cancer
Categories
Funding
- National Natural Science Foundation of China (NSFC) Key Project [81130046]
- NSFC [81171993, 81272415]
- Guangxi Key Projects [2013GXNSFEA053004]
- Guangxi Projects [1355004-5, 2012GXNSFCB053004]
- Guangxi Ministry of Education [201202ZD022, 201201ZD004]
Ask authors/readers for more resources
Metformin, an inexpensive and well-tolerated oral agent commonly used in the first-line treatment of type 2 diabetes, has become the focus of intense research as a candidate anticancer agent. Here, we discuss the potential of metformin in cancer therapeutics, particularly its functions in multiple signaling pathways, including AMP-activated protein kinase, mammalian target of rapamycin, insulin-like growth factor, c-Jun N-terminal kinase/mitogen-activated protein kinase (p38 MAPK), human epidermal growth factor receptor-2, and nuclear factor kappaB pathways. In addition, cutting-edge targeting of cancer stem cells by metformin is summarized.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available